ARTICLE | Finance

Quark gets specific

Why Quark Venture backed antibiotics company Abac

February 16, 2018 8:04 PM UTC

Abac Therapeutics S.A.’s targeted approach to antibiotic development led Quark Venture to join the company’s €16 million ($19.6 million) series A round, which will enable it to bring its lead program into the clinic.

Pontifax led the round, which closed on Feb. 15. Fellow new investors GF Securities Co. Ltd. (SZSE:00076; HKSE:1776), Caixa Capital Risc, Debiopharm Innovation and existing investor Grupo Ferrer Internacional S.A. also participated...